VEGFA and hepatocellular carcinoma: In addition, the results of the phase I/II trial of the COSMIC-312 trial showed that the combination of cabozantinib, a multikinase inhibitor with VEGF-inhibitory activity, and atezolizumab had favorable therapeutic effects in metastatic HCC [11].